Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

8.000 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 441,210
Open 8.000
Bid (Size) 7.970 (100)
Ask (Size) 8.000 (2,000)
Prev. Close 8.000
Today's Range 8.000 - 8.000
52wk Range 1.950 - 12.43
Shares Outstanding 391,156,513
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
ImmunityBio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of NAI + BCG Versus Nadofaragene and TAR-200 at AUA 2026
From ImmunityBio, Inc.
Via Business Wire
News headline image
IMMUNITYBIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Urges Immunity Bio, Inc. Stockholders with Significant Losses to Contact the Firm Regarding Their Rights Before May 26th
From Bragar Eagel & Squire
Via GlobeNewswire

Performance

YTD
+296.0%
+296.0%
1 Month
-2.4%
-2.4%
3 Month
+32.9%
+32.9%
6 Month
+294.1%
+294.1%
1 Year
+185.7%
+185.7%

More News

Read More
News headline image
IMMUNITYBIO DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
ImmunityBio Announces Comprehensive U.S. Patents Covering Combination of ANKTIVA with BCG for Cancer Treatment, with Terms Through 2035
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States
From ImmunityBio, Inc.
Via Business Wire
News headline image
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
IMMUNITYBIO, INC. INVESTORS WITH LOSSES HAVE UNTIL MAY 26, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase
Via FinancialNewsMedia
News headline image
ImmunityBio, Inc. (IBRX) Action Lawsuit: Investors Face May 26, 2026, Deadline
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
ImmunityBio, Inc. (IBRX) Action Lawsuit: Investors Face May 26, 2026, Deadline
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
From Kahn Swick & Foti, LLC
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines – IBRX
From Pomerantz LLP
Via GlobeNewswire
News headline image
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against ImmunityBio, Inc. (IBRX)
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
ImmunityBio, Inc. (NASDAQ: IBRX) Investors Who Have Suffered Losses - Contact Kaplan Fox before May 26, 2026 Lead Plaintiff Deadline
Via NewMediaWire
Topics Lawsuit
News headline image
ImmunityBio, Inc. (NASDAQ: IBRX) Investors Who Have Suffered Losses - Contact Kaplan Fox before May 26, 2026 Lead Plaintiff Deadline
Via TheNewswire.com
Topics Lawsuit
News headline image
ImmunityBio, Inc. Investors: May 26, 2026, Deadline in Securities Fraud Class Action Lawsuit
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
ImmunityBio, Inc. Investors: May 26, 2026, Deadline in Securities Fraud Class Action Lawsuit
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
ImmunityBio, Inc. (NASDAQ: IBRX) Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
ImmunityBio, Inc. (NASDAQ: IBRX) Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
INVESTOR DEADLINE REMINDER: ImmunityBio, Inc. (IBRX) Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
INVESTOR DEADLINE REMINDER: ImmunityBio, Inc. (IBRX) Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Via TheNewswire.com
Topics Fraud Lawsuit

Frequently Asked Questions

Is ImmunityBio, Inc. - Common Stock publicly traded?
Yes, ImmunityBio, Inc. - Common Stock is publicly traded.
What exchange does ImmunityBio, Inc. - Common Stock trade on?
ImmunityBio, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for ImmunityBio, Inc. - Common Stock?
The ticker symbol for ImmunityBio, Inc. - Common Stock is IBRX on the Nasdaq Stock Market
What is the current price of ImmunityBio, Inc. - Common Stock?
The current price of ImmunityBio, Inc. - Common Stock is 8.000
When was ImmunityBio, Inc. - Common Stock last traded?
The last trade of ImmunityBio, Inc. - Common Stock was at 05/18/26 04:00 PM ET
What is the market capitalization of ImmunityBio, Inc. - Common Stock?
The market capitalization of ImmunityBio, Inc. - Common Stock is 3.13B
How many shares of ImmunityBio, Inc. - Common Stock are outstanding?
ImmunityBio, Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.